Type 2N von Willebrand disease: genotype drives different bleeding phenotypes and treatment needs
Journal of Thrombosis and Haemostasis · 2024
DOI: 10.1016/j.jtha.2024.06.020 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Thrombosis and Haemostasis, 2024. Verfasst von Mélanie Y Daniel und 22 weiteren Autor:innen. Beteiligte Einrichtung: Hematology and Transfusion Department, Institut National de la Santé et de la Recherche Médicale, Centre Hospitalier Universitaire de Lille, Institut…. Hauptthemen laut MEDLINE: Deamino Arginine Vasopressin, Phenotype, Hemorrhage, von Willebrand Disease, Type 2. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 42 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: Type 2 Normandy von Willebrand disease (VWD2N) is usually perceived as a mild bleeding disorder that can be treated with desmopressin (DDAVP). However, VWD2N patients can be compound heterozygous or homozygous for different variants, with p.Arg854Gln (R854Q) being the most frequent causative one. There are limited data about the impact of 2N variants on VWD2N phenotype and DDAVP response. OBJECTIVES: This study aims to describe the phenotype of VWD2N, including DDAVP response, according to genotype. METHODS: VWD2N patients with a complete genotype/phenotype characterization by the French reference center for VWD, including MCMDM-1VWD bleeding score, were eligible to be included in the study. Results of the DDAVP trial were also collected. RESULTS: A total of 123 VWD2N patients from the French registry were included in this study. Results were stratified according to the presence (R854QPos, n = 114) or absence (R854QNeg, n = 9) of at least 1 R854Q allele. Three R854QPos subgroups were further individualized: patients homozygous (R854QHmz, n = 55), compound heterozygous for R854Q and a null allele (R854Q/3, n = 48), or compound heterozygous for R854Q and another 2N variant (R854Q/2N, n = 11). FVIII: C levels were significantly lower in R854QNeg and R854Q/3 patients compared with R854QHmz ones (P < .001 and P < .0001, respectively). R854QNeg patients were diagnosed earlier due to bleeding symptoms and had a higher bleeding score than R854QPos patients (P < .001). In DDAVP trial, FVIII:C survival was lower in VWD type 2N than in type 1 patients. R854QPos patients had a heterogeneous DDAVP response, which was best predicted by baseline FVIII:C level. CONCLUSION: The heterogeneous genetic background of VWD2N drives different bleeding phenotypes and response patterns to DDAVP, underlining the clinical relevance of DDAVP trial to identify patients potentially eligible to alternative therapeutic options.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Hematology and Transfusion Department, Institut National de la Santé et de la Recherche Médicale, Centre Hospitalier Universitaire de Lille, Institut Pasteur de Lille, Université de Lille, U1011-European Genomic Institu…
- Haemostasis Clinical Center, Nantes University Hospital, Nantes, France.
- Bordeaux University Hospital, Hemostasis Clinical Center, Bordeaux, France.
- Hemostasis Clinical Center, Marseille University Hospital, Assistance Publique-Hôpitaux de Marseille, Marseille, France.
- Reference Center for Hemophilia and Rare Congenital Bleeding Disorders, Bicêtre Hospital Assistance Publique-Hôpitaux de Paris, University of Paris-Saclay and Unité Mixte de Recherche_S1176, Institut National de la Sant…
- Hemostasis Clinical Center, Dijon University Hospital, Dijon, France.
Zitieren
APA
Daniel, M. Y., Ternisien, C., Castet, S., Falaise, C., D'Oiron, R., Volot, F., Itzhar, N., Pan-Petesch, B., Jeanpierre, E., Paris, C., Zawadzki, C., Desvages, M., Dupont, A., Veyradier, A., Repessé, Y., Babuty, A., Trossaërt, M., Boisseau, P., Denis, C. V., …, & Susen, S. (2024). Type 2N von Willebrand disease: genotype drives different bleeding phenotypes and treatment needs. Journal of Thrombosis and Haemostasis. https://doi.org/10.1016/j.jtha.2024.06.020
Vancouver
Daniel MY, Ternisien C, Castet S, Falaise C, D'Oiron R, Volot F, et al. Type 2N von Willebrand disease: genotype drives different bleeding phenotypes and treatment needs. Journal of Thrombosis and Haemostasis. 2024. doi:10.1016/j.jtha.2024.06.020
BibTeX
@article{Daniel2024,
author = {Daniel, Mélanie Y and Ternisien, Catherine and Castet, Sabine and Falaise, Céline and D'Oiron, Roseline and Volot, Fabienne and Itzhar, Nathalie and Pan-Petesch, Brigitte and Jeanpierre, Emmanuelle and Paris, Camille and Zawadzki, Christophe and Desvages, Maximilien and Dupont, Annabelle and Veyradier, Agnès and Repessé, Yohann and Babuty, Antoine and Trossaërt, Marc and Boisseau, Pierre and Denis, Cécile V and Lenting, Peter J and Goudemand, Jenny and Rauch, Antoine and Susen, Sophie},
title = {Type 2N von Willebrand disease: genotype drives different bleeding phenotypes and treatment needs},
journal = {Journal of Thrombosis and Haemostasis},
year = {2024},
doi = {10.1016/j.jtha.2024.06.020}
}
EUVIMED